Cell Signaling Technology

Product Pathways - Adhesion

uPAR Antibody #9692

Applications Reactivity Sensitivity MW (kDa) Source
W H Endogenous 65 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

uPAR Antibody recognizes endogenous levels of total uPAR protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr109 of human uPAR protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western blot analysis of extracts from U-937 cells, pre-incubated with TPA #4174 (200 nM, 72 hr) and either left untreated (-) or treated (+) with PNGaseF, using uPAR Antibody.

Background

The human urokinase-type plasminogen activator receptor (uPAR) is a 55-65 kDa, highly glycosylated, GPI-anchored cell surface receptor (the deglycosylated protein is 35 kDa) (1-3). It is a central player in the plasminogen activation pathway. uPAR binds with high affinity to a serine protease urokinase-type plasminogen activator (uPA) and converts plasminogen to its active form plasmin in a spatially restricted manner on the cell surface (4). Plasmin further carries out the activation of uPA, which is inhibited by serpins, such as plasminogen activator inhibitors (5). Therefore, uPAR plays a key role in regulating extracellular proteolysis. In addition, uPAR plays an important role in regulating cell proliferation, adhesion, and mobility (6,7). Research studies have shown that overexpression of uPAR is found in various cancer cells and tissues (8,9).

  1. Nielsen, L.S. et al. (1988) J Biol Chem 263, 2358-63.
  2. Behrendt, N. et al. (1990) J Biol Chem 265, 6453-60.
  3. Roldan, A.L. et al. (1990) EMBO J 9, 467-74.
  4. Ellis, V. et al. (1991) J Biol Chem 266, 12752-8.
  5. Ellis, V. et al. (1990) J Biol Chem 265, 9904-8.
  6. Liu, D. et al. (2002) Cancer Cell 1, 445-57.
  7. Waltz, D.A. et al. (1997) J Clin Invest 100, 58-67.
  8. Blasi, F. and Sidenius, N. (2010) FEBS Lett 584, 1923-30.
  9. Mazar, A.P. et al. (2011) Curr Pharm Des 17, 1970-8.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products